Begin typing your search above and press return to search.
exit_to_app
Five years on,  Najeeb still missing
access_time 2021-10-14T11:35:37+05:30
access_time 2021-10-13T13:28:12+05:30
More than just an award, a message
access_time 2021-10-11T09:31:16+05:30
Facebook with a saffron tinge
access_time 2021-10-09T11:15:52+05:30
Monson: A prophet for our fake news times
access_time 2021-10-09T10:08:19+05:30
DEEP READ
exit_to_app
Homechevron_rightIndiachevron_rightWHO's emergency...

WHO's emergency approval for Covaxin expected soon: Health Ministry

text_fields
bookmark_border
WHOs emergency approval for Covaxin expected soon: Health Ministry
cancel

New Delhi: The Health Ministry on Wednesday hinted that the World Health Organization (WHO)'s Emergency Use Authorization (EUA) for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected soon.

The Hyderabad-based drug manufacturer has asserted that it has submitted all data required for clearance. According to them, Phase III clinical trials of Covaxin had demonstrated an efficacy rate of 77.8 per cent.

The indigenously developed vaccine is yet to receive the Emergency Use Authorisation from the World Health Organisation.

Sources said Covaxin has been "recognised in 22 countries so far and hopefully, it will be approved by WHO soon".

The world health body had delayed the clearance on Covaxin, seeking more technical information from the manufacturer, Bharat Biotech.

On October 5, the World Health Organisation held out hope for a speedy green signal, tweeting, "WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin."

Bharat Biotech "has been submitting data to the WHO on a rolling basis and submitted additional info at WHO's request on 27 September", another tweet read.

The push for international clearance for Covaxin -- approved by the Indian Drug Controller in January -- has been on for months. The dossier of Bharat Biotech has been under review by technical experts for consideration since July.

The vaccine has received a green signal from an expert committee for use in children above the age of 2 years and is now waiting for approval from the country's drug control authority.

Show Full Article
TAGS:WHO Covaxin 
Next Story